NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex
MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide,...
Dec 7, 2022
1,548
NCT05519085: Phase 3: CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM -SUCCESSOR-1
(SUCCESSOR-1) CC-92480 - Mezi - Mezigdomide - CELMoD NCT05519085: Phase 3: A Study to Evaluate CC-92480, Bortezomib and Dexamethasone...
Dec 1, 2022
207
NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients
BOREALIS Trial - CMRG 010 NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients Study of...
Dec 1, 2022
187
NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma
CELMoD - CC-92480 - Mezigdomide - MEZI NCT05372354: Phase 1/2: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480...
Dec 1, 2022
426
NCT05552222: Phase 3: Teclistamab-Daratumumab-Len (Tec-DR) Vs Dara-Len-dex (DRd) (MajesTEC-7) NDMM
(MajesTEC-7) Newly diagnosed Multiple Myeloma NCT05552222: Phase 3: A Study to Compare Teclistamab in Combination With Daratumumab and...
Dec 1, 2022
900
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa (Formerly TAK-573)...
Dec 1, 2022
135
NCT05317416: Phase 3: Elranatamab Versus Lenalidomide in Patients With NDMM post ASCT - MagnetisMM-7
MagnetisMM-7 NCT05317416: Phase 3: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After...
Dec 1, 2022
1,531
NCT04721002: Evaluate t(11;14) Status & BCL2 Expression in Adult Participants With MM (MEDICI)
NCT04721002: Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM) (MEDICI) NCT04721002:...
Dec 18, 2021
78
Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of RRMM
1676 Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician’s Choice in the Treatment of Patients with Relapsed or Refractory...
Dec 11, 2021
73
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - MajesTEC-3
MajesTEC-3 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and...
Dec 3, 2021
1,063
NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
MagnetisMM-5 Relapsed Refractory Multiple Myeloma NCT05020236: Phase 3 - MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and...
Dec 1, 2021
860
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy NCT05090566: Phase 2: MagnetisMM-4: Umbrella Study of...
Dec 1, 2021
241
NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM- (No ASCT planned) CARTITUDE-5
CARTITUDE-5 Phase 3 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against...
Dec 1, 2021
2,968
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...
Aug 7, 2021
861
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04973605: Phase 1/2: A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in...
Aug 7, 2021
59
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in...
Aug 6, 2021
237
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...
Aug 6, 2021
766
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint
NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM A...
Jun 10, 2021
132
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma Blood Cancer J; 2021...
Jun 10, 2021
136